|
Patients completed all study parts
|
n = 42
|
|---|
|
Age years (mean, range)
|
63 (35–89)
|
|
Tumor size mm (mean, range)
|
21 (6–33)
|
|
Positive nodal status
|
17 (41%)
|
|
Tumor grade (NHG)
| |
|
I
|
9 (21%)
|
|
II
|
17 (41%)
|
|
III
|
16 (38%)
|
|
Mitotic index
| |
|
1
|
23 (55%)
|
|
2
|
5 (12%)
|
|
3
|
14 (33%)
|
|
ER (n = 30)
| |
|
Positive
|
27 (90%)
|
|
Negative
|
3 (10%)
|
|
PR (n = 30)
| |
|
Positive
|
24(80%)
|
|
Negative
|
6 (20%)
|
|
HER2 (n = 29)
| |
|
0
|
7 (24%)
|
|
1+
|
10 (34%)
|
|
2+
|
7 (24%)
|
|
3+
|
5 (17%)
|
|
Ki67 index (n = 26)
| |
|
Low
|
15 (58%)
|
|
High
|
11 (42%)
|
|
HMGCR (n = 38)
| |
|
Positive
|
24 (63%)
|
|
Negative
|
14 (37%)
|
- NHG Nottingham histologic grade I-III (post-treatment pathological report), Mitotic index according to Nottingham criteria (post-treatment pathological report).
- Baseline tumor data (pre-treatment): ER (estrogen receptor), PR (progesterone receptor), HER2 (human epidermal growth factor receptor 2), Ki67 high if >20%, HMGCR positive if any cytoplasmic staining.
